Needham Estimates PhaseBio Pharma’s Bentracimab Market Opportunity Of Up To $1.5B
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) remains on track to complete the bentracimab biologics license application (BLA) filing around mid-2022 for bleeding risks associated with using ticagrelor antiplatelet drug.
53 Biggest Movers From Yesterday
Gainers
MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 64.4% to close at $1.41 on Thursday. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.
PhaseBio Announces Results From Phase 2b Trial For Bentracimab; Co. Reports ‘Trial achieved primary reversal endpoint in older volunteers’
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced the complete
Looking Into PhaseBio Pharmaceuticals’s Return On Capital Employed
Benzinga Pro data, PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported Q4 sales of $158.00 thousand. Earnings fell to a loss of $43.11 million, resulting in a 35.04% decrease from last quarter.
63 Biggest Movers From Yesterday
Gainers
InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire.